en · de · es · fr · pt
cardarine-notes.peptides6908.com › Faq › Cardarine As Investigational Pparδ Agonist — Explained

Cardarine As Investigational Pparδ Agonist — Explained

By Editorial Desk · published 2025-07-14 · last reviewed 2025-08-31 · Faq

A practical reference on Nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-08-31. Anything still debated is marked as such rather than presented as settled.

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Mechanism and Detection

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

Related pages on this site

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Background from the literature

=== Soviet use of RTGs === Many Beta-M RTGs produced by the Soviet Union to power lighthouses and beacons have become orphaned sources of radiation. Its design allowed for the use of normal industrial bolts instead of intrinsically safe or safety interlocked bolts (most likely to reduce cost), and did not require the use of intrinsically safe opening mechanisms or made any use of tamper resistant shielding systems. Several of these units have also been illegally dismantled for scrap metal, or been exposed to storm conditions, freezing and water penetration, common issues in those abandoned in the harsh Russian arctic. Some have even fallen into the ocean, or have defective shielding due to poor design or physical damage. The US Department of Defense cooperative threat reduction program has expressed concern that material from the Beta-M RTGs can be used by terrorists to construct a dirty bomb. However, the strontium titanate perovskite used is resistant to all likely forms of environmental degradation and cannot melt or dissolve in water. Bioaccumulation is unlikely as SrTiO3 passes through the digestive tract of humans or other animals unchanged, but the animal or human who ingested it would still receive a significant radiation dose to the sensitive intestinal lining during passage. Mechanical degradation of "pebbles" or larger objects into fine dust is more likely and could disperse the material over a wider area, however this would also reduce the risk of any single exposure event resulting in a high dose.

(CH2CH2)O + H2O → HO–CH2CH2–OH The reaction also occurs in the gas phase, in the presence of a phosphoric acid salt as a catalyst. The reaction is usually carried out at about 60 °C (140 °F) with a large excess of water, in order to prevent the reaction of the formed ethylene glycol with ethylene oxide that would form di- and triethylene glycol:

Bill Browder (born 23 April 1964) of Russian Jewish ancestry; author, financier and political activist; CEO and co-founder of Hermitage Capital Management, investment advisor to the Hermitage Fund, which was the largest foreign portfolio investor in Russia; published Red Notice: A True Story of High Finance, Murder, and One Man's Fight for Justice, focusing on his years spent in Russia. A film adaptation written by William Nicholson was reportedly in the works in 2015. A new book by Browder was published on 12 April 2022: Freezing Order: A True Story of Money Laundering, Murder and Surviving Vladimir Putins Wrath. Rivkah Brown; editor of Vashti Media and Novara Media; critic of the concept of the New antisemitism, critic of Israel and Zionism, writes for The Guardian, The Independent, the London Review of Books, The Financial Times and New Statesman. Novara Media (often shortened to Novara) is an independent, left-wing alternative media organisation based in the United Kingdom.

== Development == Dermal macrophages are either from embryonic progenitors or circulating progenitors. Numerous dermal macrophages are present in the skin at birth due to the infiltration of yolk-sac derived macrophages and haematopoietic stem cell (HSC)-derived monocytes. The prenatal population of dermal macrophages is gradually replaced by the recruitment and differentiation of circulating progenitors in adulthood. Prenatal dermal macrophages are not to be confused with Langerhans cells as they uniquely express CD14 and FXIIIa and lack CD1a.

=== Refrigeration === Around 1938, following a request by Numero, Jones began designing the Thermo Control Model A automatic truck refrigeration unit. Jones designed the portable air-cooling unit for trucks carrying perishable food to prevent spoilage. The Model A refrigeration equipment was attached to undercarriages of trucks. Chilled air was transported to the inside of the trailer via refrigerant tubing. Because Model A was too heavy, Jones later developed the Model B, which was smaller and lighter, but not durable. In 1941, Jones completed development of the Model C, which was mounted to the front of the truck, was compact, light, and withstood road travel vibrations. In 1939, Jones filed for a patent for the Model A and received a patent for it on July 12, 1949. Numero sold his movie sound equipment business to RCA and formed a new company in partnership with Jones, the U.S. Thermo Control Company (later the Thermo King Corporation) which became a $3 million business by 1949. Portable cooling units designed by Jones were especially important during World War II, preserving blood, medicine, and food for use at army hospitals and on open battlefields. Model C units were initially manufactured for military use, but following the war the units became available for commercial use as well.

Sources: en.wikipedia.org

Reference notes

=== Drug discovery problems === In September 2005, Dr. Reddy's spun off its drug discovery and research wing into a separate company called Perlecan Pharma Private Limited. At the time, this was hailed as an innovative move, but in 2008, the company had to be wound down due to funding constraints. Dr. Reddy's was the first Indian pharma company to attempt such an effort to de-couple risk of drug discovery from the parent company by creating a separate company with an external source of funding. Perlecan Pharma was partially funded by ICICI Venture Capital and Citigroup Venture International, both of which held a 43% stake in Perlecan for an estimated $22.5 million. However, the company was forced to buy back the Perlecan shares from ICICI and Citigroup due to doubts regarding the commercial viability of the drug candidates that were in Perlecan's pipeline. At that point, Perlecan became a wholly owned subsidiary. In the board meeting of 23 October 2008, the company chose to amalgamate/absorb Perlecan, thereby making it an in-house research facility, as it was before 2005. In 2009, the company did a U-turn and has handed over discovery research and related intellectual property to its Bangalore-based subsidiary, with the possibility of spinning it off as a different entity altogether. "The company may be hoping to find a strategic partner in the future to share the risks and research funding."

=== Outer membrane and surface antigens === The of T. pallidum has several features that have made it historically difficult to research. These include details such as its fragility. The treponemal outer membrane (OM) proteins are key factors for the bacterium's pathogenesis, persistence, and immune evasion strategies. Treponema's reputation as a "stealth pathogen" is primarily due to this unique (OM) structure, which serves to evade immune detection. The outer membrane of Treponema pallidum contains a strikingly low concentration of transmembrane proteins, approximately 100-fold lower than other gram-negative bacteria or other spirochetes. This protects the cells from antibodies attacking it, hence they exhibit a "puzzling lack of antigenicity". The genome also revealed a bundle of 12 proteins and some putative hemolysins are potential virulence factors of T. pallidum. One protein, TprK, appears to constantly mutate to avoid immune response from its host.

It has been suggested that suicidal behavior and ideation may be associated with use of GLP-1 receptor-agonist medication, but studies in several countries since 2024 do not support this. In January 2026, the US Food and Drug Administration requested removal of a suicidal behavior and ideation warning from GLP-1 receptor-agonist medications.

=== Leucomatous corneal opacity (leucoma simplex) === Leucomatous corneal opacity is a dense white opacity which results due to scarring of more than half of the stroma. A number of different presentations of leucomatous corneal opacity exist:

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.

Network